---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-040728"
form_type: "8-K"
ticker: "BJDX"
cik: "0001704287"
company_name: "Bluejay Diagnostics, Inc."
filed_at: "2026-04-07T23:59:59+00:00"
generated_at: "2026-05-15T07:03:23.713323+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Bluejay Diagnostics completes 624 of 750 patient enrollments in SYMON-II sepsis trial

## Summary
- SYMON-II pivotal trial for Symphony IL-6 sepsis triage test enrolled 624 of 750 target patients.
- Enrollment completion expected within 2-3 months, subject to site activity and patient flow.
- Inclusion and exclusion criteria have not caused significant patient exclusions, per CEO Neil Dey.

## SEC filing metadata
- accession: 0001213900-26-040728
- form_type: 8-K
- ticker: BJDX
- cik: 0001704287
- company_name: Bluejay Diagnostics, Inc.
- filed_at: 2026-04-07T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1704287/000121390026040728/0001213900-26-040728-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1704287/000121390026040728/ea0285343-8k_bluejay.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-040728
- JSON: https://secwatch.observer/filing/0001213900-26-040728.json
- Plain text: https://secwatch.observer/filing/0001213900-26-040728.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.